JP Morgan Chase
BRNS

JP Morgan Chase’s Barinthus Biotherapeutics BRNS Stock Holding History

JP Morgan Chase’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed – – 6471
2022
Q2 		$0 Sell
6
-11
-65% -$53 ﹤0.01% 6471
2022
Q1 		$0 Buy
+17
New +$137 ﹤0.01% 6609

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's BRNS Position: Q3 2022 in Review

JP Morgan Chase sold out of Barinthus Biotherapeutics (BRNS) in Q3 2022, closing a stake of 6 shares.

JP Morgan Chase first reported a position in BRNS in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 11 funds tracked by Wall St. Rank hold BRNS as of Q3 2022.

  • JP Morgan Chase reported no remaining Barinthus Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • JP Morgan Chase sold 6 Barinthus Biotherapeutics shares in Q3 2022.
  • JP Morgan Chase first reported a position in Barinthus Biotherapeutics in Q1 2022 and held it in 2 quarters.
  • JP Morgan Chase's Barinthus Biotherapeutics position peaked at $0 in Q2 2022.
  • 11 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2022.

Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.